Regulatory 2024-05-16 | Quarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 Study PDF Report Presentation Webcast
Regulatory 2023-05-11 | QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completed PDF Report Presentation Webcast
Regulatory 2022-05-11 | Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals PDF Report Presentation Webcast
Regulatory 2021-05-12 | Quarterly Report Q1 2021: US office opened in preparation of launch PDF Report Presentation Webcast
Regulatory 2020-05-13 | Interim Financial Report Q1-2020: First patient enrolled in Phase 3 study SPARKLE PDF Report Presentation Webcast
